GlassScriptPhysician profile
Mark Laukka
NPI 1538192851
$12,754.38
in general payments reported to CMS, 2019-2025
26 companies · $2,116 in 2025
The $2,116 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $555 · 2021: $1,606 · 2022: $2,512 · 2023: $1,754 · 2024: $2,693 · 2025: $2,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,554 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,553.96 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,921.78 | 2019-2025 | |
| Gilead Sciences, INC. | $1,874.82 | 2019-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $939.94 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $839.35 | 2021-2025 | Tremfya, Stelara |
| Cook Medical LLC | $703.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $585.70 | 2021-2024 | Zeposia |
| Genzyme Corporation | $547.05 | 2022-2024 | |
| Steris Corporation | $460.90 | 2022-2024 | |
| Conmed Corporation | $437.51 | 2020-2024 | Conmed Generators, Conmed Biliary, Conmed Dilation |
| Janssen Scientific Affairs, LLC | $435.15 | 2021-2023 | Stelara |
| Madrigal Pharmaceuticals | $260.46 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $217.28 | 2022-2024 | Dupixent |
| Shire North American Group INC | $200.00 | 2019 | |
| Pfizer INC. | $196.37 | 2019-2024 | |
| Boston Scientific Corporation | $165.07 | 2022-2025 | Wallflex Duodenal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $161.87 | 2023 | Rebyota |
| Allergan, INC. | $161.69 | 2019 | |
| Intercept Pharmaceuticals, INC. | $125.00 | 2024 | |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Phathom Pharmaceuticals, INC. | $96.44 | 2024 | Voquezna |
| Ardelyx, INC. | $87.36 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $85.96 | 2025 | Iqirvo |
| Enterra Medical, INC. | $84.16 | 2023 | |
| Covidien LP | $33.28 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Laukka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.